2025
N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis
Mapamba D, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, Mtafya B, Kibona M, Bakuli A, Rachow A, Velen K, Hoelscher M, Ntinginya N, Charalambous S, Churchyard G, Wallis R, consortium T. N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis. Journal Of Infection 2025, 90: 106379. PMID: 39756697, DOI: 10.1016/j.jinf.2024.106379.Peer-Reviewed Original ResearchAdjunctive N-acetylcysteineN-acetylcysteinePulmonary tuberculosisEx vivo whole blood cultureAffecting IL-10Effect of N-acetylcysteineFar-advanced pulmonary tuberculosisRecovery of lung functionN-acetylcysteine treatmentWhole blood culturesHost-directed therapiesPost-tuberculosis lung diseaseReduction of oxidative stressClearance of MtbAnti-inflammatory effectsBiomarkers of oxidationBlood culturesSecondary endpointsTotal glutathionePreclinical modelsClinical outcomesMtb burdenMonth 1Healthy volunteersIL-10
2024
P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized Estimating EquationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonthsIron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19
Hanson A, Mulè M, Ruffieux H, Mescia F, Bergamaschi L, Pelly V, Turner L, Kotagiri P, Göttgens B, Hess C, Gleadall N, Bradley J, Nathan J, Lyons P, Drakesmith H, Smith K. Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19. Nature Immunology 2024, 25: 471-482. PMID: 38429458, PMCID: PMC10907301, DOI: 10.1038/s41590-024-01754-8.Peer-Reviewed Original ResearchConceptsStress erythropoiesisNumbers of dendritic cellsLow serum ironSARS-CoV-2Long-term outcomesWeek of diseaseIncreased iron demandOutcomes of COVID-19SARS-CoV-2 infectionCOVID-19 symptom onsetCOVID-19 severityDendritic cellsPersistent symptomatologyMonth 1Serum ironProliferating lymphocytesIron homeostasisUnresolved inflammationSymptom onsetPersistent symptomsHospitalized patientsDysregulated erythropoiesisInflammatory disequilibriumLong-term outcomes of COVID-19Iron homeostasis gene expression503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Wang Z, Martins B, Ardeleanu M, Yang M, Bégo-Le-Bagousse G, Sierka D, Strober B. 503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice. British Journal Of Dermatology 2024, 190: ii9-ii9. DOI: 10.1093/bjd/ljad498.011.Peer-Reviewed Original ResearchHealth statusIndividual patient levelTreatment satisfactionAtopic Dermatitis Control ToolPatient levelQuality of life of childrenObservational study of adultsAtopic dermatitisLongitudinal cohort studyPatient-reported outcomesPatient support programStudy of adultsQuality of lifeDupilumab treatmentMonth 1Lives of childrenBaseline surveyChronic inflammatory skin diseasePatients maintained responseSupport programsModerate-to-severe ADCohort studyLong-term treatmentInflammatory skin diseaseOutcome trajectories
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply